Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Endo Pharmaceuticals Stories

2012-10-31 15:25:58

MISSISSAUGA, ON, Oct. 31, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the third quarter ended September 30, 2012. Third Quarter and Recent Corporate Developments: -- The Company was informed by Galderma that it has received U.S....

2012-10-29 15:26:30

- Third quarter results to be released after market close on October 31, 2012 - MISSISSAUGA, Oct. 29, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced it will host a conference call on Thursday, November 1, 2012 at 8:30 a.m. (ET) to discuss its 2012 third quarter financial results....

2012-10-22 07:29:00

MISSISSAUGA, ON, Oct. 22, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Pliaglis® (lidocaine/tetracaine) 7%/7% Cream.  Nuvo has licensed worldwide...

2012-09-28 06:24:18

CHADDS FORD, Pa., Sept. 28, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced the appointment of Jill D. Smith to the company's board of directors. Ms. Smith, an international business leader for more than 25 years, including 16 years as a CEO of private and public companies in the technology and information services markets, was most recently chairman, CEO and president of DigitalGlobe Inc., a provider of satellite imagery products and services to governments and...

2012-09-28 06:24:07

CHADDS FORD, Pa., Sept. 28, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that it will host an Investor Meeting on Oct. 4, 2012, in New York City. The company will provide a live audio and slide webcast of this Investor Meeting beginning at 9:00 a.m. ET on Oct. 4, 2012. The meeting is expected to conclude by 12:30 p.m. ET. David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of...

2012-09-26 10:24:30

CHADDS FORD, Pa., Sept. 26, 2012 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions (Nasdaq: ENDP), announced today that the company has received Paragraph IV Certification Notices from Teva Pharmaceuticals and Amneal Pharmaceuticals each advising of the filing of Abbreviated New Drug Applications (ANDAs) for generic versions of OPANA(®) ER (Oxymorphone HCl). Endo intends to vigorously defend OPANA ER's intellectual property rights and will pursue all...

2012-09-06 02:32:21

CHADDS FORD, Pa., Sept. 6, 2012 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), today announced that, according to the latest IMS data estimates, the reformulated OPANA(®) ER (oxymorphone HCl) incorporating Grunenthal's INTAC(®) Technology designed to be crush-resistant accounts for more than 90 percent of the OPANA ER total prescription volume. "Patient safety, including appropriate use of our products, remains one of Endo's...

2012-09-05 10:26:08

CHADDS FORD, Pa., Sept. 5, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that Julie McHugh, chief operating officer, will present a corporate overview at the UBS 2012 Global Life Sciences Conference on Wednesday, Sept. 19, 2012, at 2:00 p.m. ET. The conference will be held at the Grand Hyatt in New York City. A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/. Click on Investor...

2012-08-23 14:22:18

CHADDS FORD, Pa., Aug. 23, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today issued the following statement regarding the U.S. Food and Drug Administration's (FDA) response to Endo's Citizen Petition (CP) related to the approval requirements for generic versions of LIDODERM (lidocaine patch 5%), a locally-acting topical medication for the relief of pain associated with post-herpetic neuralgia. "We are disappointed in FDA's decision to deny the citizen petition and approve a...

2012-08-23 10:24:39

PARSIPPANY, N.J., Aug. 23, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm(®). Watson plans to launch the product in September of 2013 pursuant with its settlement agreement with Endo Pharmaceuticals Inc. and...